+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06248606

Phase 2 Trial of Adagrasib Combined with Stereotactic Radiosurgery for Treating Brain Metastases in Patients with KRAS G12C-Mutated Metastatic Non-Small Cell Lung Cancer

Led by Ryan Gentzler, MD · Updated on 2026-04-08

30

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of stereotactic radiosurgery SRS and the drug adagrasib for treating brain metastases in patients with KRAS G12C-mutated non-small cell lung cancer NSCLC. This phase 2 trial aims to assess how well this treatment controls intracranial disease. The study plans to enroll 30 patients to better understand the effects of this combined approach. All participants will receive oral adagrasib at a dose of 600mg twice daily in treatment cycles. SRS will be delivered as part of standard care, occurring between 4 weeks before and up to 3 weeks after starting adagrasib. Adagrasib dosing will pause the day before and the day of SRS treatment. There is no set maximum duration for receiving adagrasib. Some patients may have had SRS prior to joining the study. Participants will be monitored closely with evaluations of disease control in the brain at 3 months as the primary outcome. Additional measures include overall response rates, progression-free survival, overall survival, and adverse events over 52 months. Researchers will collect health data throughout to assess treatment impact and safety. Participation involves ongoing assessments and treatments under medical supervision until study completion or discontinuation.

CONDITIONS

Brief Title

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Research Team

R

Ryan Gentzler, MD, MS

A

Amber Ryba

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here